Research programme: cancer therapeutics - Daiichi Sankyo

Drug Profile

Research programme: cancer therapeutics - Daiichi Sankyo

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Daiichi Sankyo Company; Rigel Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 12 Dec 2016 Daiichi Sankyo forms a strategic partnership with DarwinHealth to prioritise investigational compounds based on tumour checkpoints for clinical development
  • 24 Nov 2015 Rigel Pharmaceuticals and Daiichi Sankyo enters into a collaboration for discovering and developing MDM2 inhibitors in Cancer (Rigel Pharmaceuticals pipeline) before November 2015
  • 31 Dec 2013 A lead candidate from this programme has entered clinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top